LONDON – In January 2023, the US FDA granted mRNA-1345 Breakthrough Therapy Designation for the prevention of RSV-LRTD in adults aged 60 years or older, and mRNA-1345 was previously granted Fast Track designation by the U.S. FDA in August 2021.“We’ve seen the impact that respiratory viruses like RSV can have on the health and wellbeing of Canadians. As we approach …
Washington – There are no shortcuts when developing safe and effective medicines. On average, it can take 10-15 years to bring a new medicine from early-stage research through clinical trials. The reality is, despite recent scientific advances, there are many serious and life-threatening diseases that lack meaningful treatments, therapies, or cures. Waiting a decade could be the difference between life …
